Close Menu
    What's Hot

    Royal Horticultural Society 1974 Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

    August 17, 2026

    Athora To Sell German Business to Frankfurter Leben

    August 17, 2026

    The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

    August 13, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Royal Horticultural Society 1974 Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      August 17, 2026

      Athora To Sell German Business to Frankfurter Leben

      August 17, 2026

      Talcott Financial Group, Goldman Sachs Launch West Grove Re

      August 5, 2026

      Lincoln Financial Reinsures Universal Life Block With Talcott

      August 3, 2026

      US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

      August 13, 2026

      Shaping the Future of Health Insurance Through Innovation and Analytics

      June 10, 2026

      Q&A: Dr Christoph Schmitt, Director, Insurance, Fitch Ratings

      May 28, 2026

      Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

      May 13, 2026

      US Life Carriers Eyeing VM-22 for a Pension Risk Transfer Pricing Advantage in 2027

      August 12, 2026

      Elementis Group Pension Scheme Completes Bulk Purchase Annuity Buy-In With Aviva

      August 5, 2026

      Hickson UK Group Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      August 3, 2026

      UK Insurance Company Pension Scheme Completes Bulk Purchase Annuity Transaction With M&G

      August 3, 2026

      Record Low Mortality Rates So Far in England and Wales in 2026

      July 9, 2026

      Organ Transplant Improvements Test Life Expectancy Assessment Models

      July 8, 2026

      The Pursuit of Everlasting Life Unlikely to Shift Actuarial Models

      June 10, 2026

      Pricing in the Unknown: Why Mortality Models Aren’t Ready for MCED Tests Just Yet

      April 9, 2026

      The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

      August 13, 2026

      New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

      August 12, 2026

      The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

      August 12, 2026

      Corry Capital Advisors Adds John Daniel as Senior Director of Analytics and AI Strategy

      August 6, 2026

      Royal Horticultural Society 1974 Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      August 17, 2026

      Athora To Sell German Business to Frankfurter Leben

      August 17, 2026

      The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

      August 13, 2026

      US Individual Life Insurance Sales Continue Growth Trend in the Second Quarter

      August 13, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 8, August 2026

      August 12, 2026

      Editor’s Letter – Volume 2, Issue 7, July 2026

      July 8, 2026

      Editor’s Letter – Volume 2, Issue 6, June 2026

      June 10, 2026

      Editor’s Letter – Volume 2, Issue 5, May 2026

      May 13, 2026

      Editor’s Letter – Volume 2, Issue 4, April 2026

      April 9, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    Q&A: Perry Koons, Director of Capital Markets, Maple Life Financial

    Secondary Life Markets July 16, 2025By Greg Winterton
    Life Risk News Q&A
    Share
    Twitter LinkedIn Email

    The life settlement secondary market saw reduced activity in 2024 for the first time in four years. Greg Winterton caught up with Perry Koons, Director of Capital Markets at life settlement provider Maple Life Financial, to get his thoughts on the state of the market as we enter the second half of the year. 

    GW: Perry, let’s start with a look back on 2024. The downturn in activity has been quite notable, but that is an aggregate view. What was the situation in the broker channel specifically last year? 

    PK: Thanks Greg. I would generally agree that the aggregate downturn the market faced last year was mirrored in the policy flow from the broker channel as well, but with a few caveats. We saw a very specific drop off in policy submissions a few months into 2024, which levelled off quickly once market pricing levels and yield requirements were reestablished. As interest rate increases resulted in less available capital in 2024, the broker channel was able to respond and avoid taking marginal value or high expectation cases to market – cases which likely would have sold in 2023 but were pricing much less attractively in 2024. 

    GW: When we spoke a couple of years ago, you mentioned that there was a trend towards concentration and maybe consolidation. Has that trend continued, and if so, will it continue still, and what might the impact be of this on the market overall? 

    PK: Yes, I think the market is still trending in that direction overall, but at a slower pace than expected. We have not seen the consolidation aspect come into play yet, more of a gentle stagnation last year when it was a down year for the market. Publicly available market data indicated the exact same number of life settlement providers reporting transactions in 2023 and 2024, just lower volume for the vast majority of them. Additionally, we did not see any notable change in the number of brokers we completed transactions with on a year over year basis. Based on this, I believe we may still be a year or two away from any significant changes, but I still believe we are heading in that direction. 

    GW: What are some of the notable trends you are seeing in terms of the features of the paper in the secondary market? Anything interesting in terms of face value, age of the insured, or carriers for example? 

    PK: Recent statistics show exactly what I would have anecdotally expected – a market that looks similar to prior years in terms of aggregate numbers, but policies with high success rates are skewing towards slightly smaller face and younger insureds than in past years. The average policy submission we have seen in 2025 averages around $1.8m, and the average insured age is 75, which sounds pretty typical. However, the average closed face amount is closer to $1.5m and we are seeing a greater number of submissions and offers on insureds below age 60 than ever before. I would also note that the average policy submitted is over 16 years from issuance, and from carriers rated A- or better with very few exceptions. So, we are dealing with very seasoned policies, more so than I’ve seen at any other point in my 20 years in the market. 

    GW: Many parties on both the broker and provider side mention the value of speeding up the process of completing a secondary market transaction. Shorter processes including reduced document packages and usage of electronic documents have been discussed as methods to achieve this goal. Have you noticed any improvements in this area? 

    PK: Yes, absolutely. A big part of our refocus at Maple in 2024 was along those exact lines. We refiled the vast majority of our state filed contract documents to allow for shorter document packages and fewer notary requirements, which benefits the end consumers as well as the brokers who serve them. We’ve also collaborated with our fund clients to be much more nimble with e-copies of documents and solving challenges with document requests from difficult insurance carriers – those delays are sometimes inevitable and understandable on 20+ year old policies but often requiring a creative solution that we can provide from our history of purchasing and diligencing thousands of policies (rather than simply playing the waiting game). I think the industry as a whole mirrors the commitment to closing more expeditiously than past years to give first time advisors and policy sellers a good experience. 

    GW: Lastly, Perry, what is the outlook for the remainder of the year in terms of secondary market activity in the broker channel? 

    PK: I am seeing a positive trend in market activity using a number of indicators. Case submission volume and total face amount submitted is up in the first six months of 2025 as compared to the six months prior. And in regard to the previous question where we discussed case trends, we are seeing the wider “buy box” driving more unique case studies and giving the broker channel additional sales strategies to pursue. In the past few months, we’ve purchased insureds in their 40s, insureds with life expectancies over 200 months, policies with face amounts below $100k, and policies over $10m – many of which received multiple offers from Maple as well as competing providers. I mention this as I still believe a healthy market is sustained by sellers having access to quality representation from the broker channel, as well as institutional capital sources having access to quality representation from the provider channel. We are optimistic this trend will continue and that policy flow will continue to increase back to levels from two-to-three years ago. 

    Perry Koons is Director of Capital Markets at Maple Life Financial 

    2025 - July Life Settlements Longevity Risk Q&A Volume 4 Issue 7 – July 2025
    Share. Twitter LinkedIn Email

    Related Posts

    The Royal Society of Chemistry Pension Scheme Completes Bulk Purchase Annuity Buy-in With PIC

    August 13, 2026By LMI Newsdesk

    New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

    August 12, 2026By Greg Winterton

    The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

    August 12, 2026By Fergus Bescoby

    Corry Capital Advisors Adds John Daniel as Senior Director of Analytics and AI Strategy

    August 6, 2026By LMI Newsdesk
    Latest Issue

    New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

    August 12, 2026

    The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

    August 12, 2026

    US Life Carriers Eyeing VM-22 for a Pension Risk Transfer Pricing Advantage in 2027

    August 12, 2026

    End-Game Clarity Shaping UK Pension Risk Transfer Market but Large Schemes Still on the Sidelines

    July 22, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.